HealthLinx Limited (HTX) has signed a licensing agreement with Sigma Aldrich for a non-exclusive upfront fees and royalty-bearing license to HealthLinx’s IgY Immunodepletion technology. The license covers Europe and Australia, with an option to expand the license into the United States upon the US Patent Office granting the patent.
Sigma Aldrich is a life science and high technology company. Its chemical and biochemical products and kits are used in scientific research including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostic and other high technology manufacturing.
HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are for diseases with high fatality; Ovarian cancer diagnostic (OvPlex) targeting US$270m pa market; Prostate cancer targeting US$350m pa market; a biomarker is a specific biochemical in the body that measures disease or the effects of treatment.
http://www.traderdealer.com.au/fundamentals/htx
Tags: Biotechnology, Healthlinx, HTX, Licensing Agreement, Ovarian cancer, Prostrate cancer
